Prometic Life Sciences Inc. announce a new management structure to provide leadership to the Corporation and the appointment of Dr. Gary Bridger, Mr. Timothy Wach and Mr. Neil Klompas to the Board of Directors. All three of these individuals will be included as nominees for election to the Board of Directors by shareholders at the upcoming Annual General and Special Meeting of the shareholders ("AGM") scheduled on June 19, 2019. Mr. David John Jeans and Ms. Louise Ménard have stepped down from the Board after having respectively served as Directors since 2017 and 2009. Also, Mr. Bruce Wendel, Chief Business Development Officer, has left the Corporation. In addition to Mr. Galbraith, the newly-appointed CEO, the Corporation's leadership team will include: Mr. Martin Leclerc, Chief Talent Officer, Dr. John Moran, Chief Medical Officer; Dr. Steven J. Burton, President of Prometic Bioseparations Ltd; Mr. Patrick Sartore, Chief Operating Officer, North America and Chief Legal Officer and Corporate Secretary and Mr. Bruce Pritchard, Chief Operating Officer, International and Chief Financial Officer. Dr. Gary Bridger has served as a member of the board of directors of X4 Pharmaceuticals Inc. since October 2018. Mr. Neil A. Klompas joined Zymeworks Inc. in March 2007 where he currently serves as Chief Financial Officer. Mr. Timothy Wach is Managing Director and Board Member of Taxand since January 2015.